Literature DB >> 1223895

Effect of amitriptyline on avoidance learning in rats following olfactory bulb ablation.

K D Cairncross, M G King, S P Schofield.   

Abstract

It has been established that following bilateral olfactory bulb ablation there occurs a performance deficit in rats exposed to aversive learning procedures. Associated with the behavioral deficit, there occurs a reduction in total cortical norepinephrine (NE). If the behavioural deficit observed is a sequitur or correlate of the NE reduction, then drug therapy aimed at increasing NE availability in the cortex should overcome the reduction in performance. Amitriptyline increases NE availability by inhibiting uptake mechanisms and increases the rate of synthesis of NE. Rats, previously bulb ablated, were treated with amitriptyline over a 10 to 14 day period and tested in aversive situations. It was demonstrated that the drug treated rats showed improved performance early in acquisition, and that the performance improvement was maintained when the treatment period was extended to 14 days. These results indicate that amitriptyline was inducing a true pharmacological effect, and that the improved performance could be correlated with increased NE availability in the cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1223895     DOI: 10.1016/0091-3057(75)90017-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  2 in total

1.  Modification by anti-depressant drugs of plasma corticosterone levels in the stressed bulbectomized rat [proceedings].

Authors:  K D Cairncross; B Cox; H Schnieden; A Wren
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

2.  Acute effects of combining citalopram and pindolol on regional brain serotonin synthesis in sham operated and olfactory bulbectomized rats.

Authors:  Khanh Q Nguyen; Yoshihiro Tohyama; Arata Watanabe; Shu Hasegawa; Ivan Skelin; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-27       Impact factor: 3.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.